Pseudohypoparathyroidism: Causes, Symptoms, and Treatment

Pseudohypoparathyroidism (PHP) is a group of rare genetic disorders in which the body produces plenty of parathyroid hormone (PTH) but cannot respond to it properly, leading to low calcium and high phosphorus in the blood despite elevated PTH levels. The root cause in most cases traces to mutations or chemical modifications at a single gene complex called GNAS on chromosome 20, and the clinical picture depends heavily on which parent passes the faulty gene along. Because the condition affects not just calcium regulation but also the body’s response to several other hormones, people with PHP can experience a surprisingly wide range of symptoms, from muscle spasms and seizures to short stature, obesity, and learning difficulties.

What Goes Wrong at the Cellular Level

Parathyroid hormone normally works by binding to receptors on kidney and bone cells, which then relay the signal inside the cell through a protein called Gsα (the alpha subunit of a stimulatory G protein). In PHP, mutations in the GNAS gene disrupt this signaling chain. The parathyroid glands keep pumping out PTH because they sense that calcium is low, but the target tissues essentially cannot hear the message. The result looks like hypoparathyroidism on blood tests, with low calcium and high phosphorus, yet PTH is paradoxically elevated rather than absent.¹

What makes GNAS unusual is that it is an imprinted gene. In most tissues, you use both copies of a gene, one from each parent. But in the kidneys, thyroid, and certain other tissues, only the copy inherited from your mother is active for Gsα production. If the mutation sits on the maternal copy, those tissues have almost no working Gsα protein, leading to hormone resistance and the full clinical syndrome of PHP type 1a.² If the same mutation is inherited from the father instead, Gsα production in those key tissues is largely unaffected, so the person may show some physical features of the condition but typically has normal calcium levels. This paternally inherited version is called pseudopseudohypoparathyroidism (PPHP).³

The Main Subtypes

PHP is not a single disease but a family of related conditions. The subtypes matter because they differ in which features appear and how severe the hormone resistance is.

PHP type 1a: Caused by inactivating mutations in the maternal GNAS allele. People with this subtype have hormone resistance (low calcium, high phosphorus, elevated PTH) and also develop a constellation of physical features known as Albright hereditary osteodystrophy (AHO). They frequently have resistance to additional hormones beyond PTH, including thyroid-stimulating hormone (TSH) and gonadotropins.⁴
PHP type 1b: Caused not by a coding mutation but by abnormal methylation patterns at the GNAS locus that reduce Gsα expression from the maternal allele. People with PHP1b have the same biochemical picture of PTH resistance but usually lack the physical features of AHO, although shortened fingers have been reported in some cases.⁵ Some autosomal dominant forms of PHP1b are linked to deletions in a nearby gene called STX16.⁶
Pseudopseudohypoparathyroidism (PPHP): Caused by paternal inheritance of the same GNAS mutations. Because the paternal allele is silenced in the tissues that matter for hormone signaling, calcium levels are normal. However, many people with PPHP still develop some AHO features such as short stature and shortened fingers.³

In practice, PHP1a is the most clinically complex subtype because it combines hormone resistance with widespread physical and developmental features. PHP1b often goes undetected longer because the physical appearance is relatively normal, and the low calcium may only come to light through routine blood work or when symptoms like tingling and muscle cramps prompt testing.

Physical Features of Albright Hereditary Osteodystrophy

The collection of physical traits called AHO appears in PHP1a and, to a variable degree, in PPHP. The hallmark is brachydactyly, especially shortening of the fourth and fifth fingers, caused by premature closure of the growth plates in certain hand and foot bones.⁷ Other common AHO features include short stature, a round face, and subcutaneous ossifications, which are small, sometimes palpable deposits of bone that form under the skin.⁸ Dental abnormalities, including enamel defects and delayed eruption of teeth, have also been reported as part of the AHO profile.⁸

Not everyone with AHO has all of these features, and the severity varies widely even within the same family. The subcutaneous ossifications, for instance, can appear at any age and in different locations. There are reports of patients developing scalp calcifications well into adulthood.⁹

Hormonal Resistance Beyond Calcium

One of the features that distinguishes PHP1a from ordinary hypoparathyroidism is that the signaling breakdown is not limited to PTH. The Gsα protein is the messenger for many different hormone receptors. In PHP1a, the same impaired signaling pathway leads to resistance to TSH (causing hypothyroidism), to gonadotropins like LH and FSH (which can cause delayed puberty or irregular menstrual cycles), and sometimes to growth-hormone-releasing hormone.¹⁰ TSH resistance is often the earliest detectable hormonal abnormality, sometimes showing up in infancy before hypocalcemia develops. This means that a child initially diagnosed with “congenital hypothyroidism” could later turn out to have PHP1a once other features emerge.

Growth hormone deficiency is strikingly common in PHP1a, found in roughly 69% of patients in one review, compared with about 0.03% in the general population.¹¹ This contributes to short stature and likely worsens other metabolic problems, so testing for growth hormone status in all PHP1a patients has been proposed as a standard recommendation.

Why Obesity Is So Persistent

Weight gain is one of the most consistent and frustrating features of PHP1a. It typically begins in early childhood and is difficult to manage through diet and exercise alone. The reason appears to be metabolic rather than behavioral. Studies comparing children with PHP1a to weight-matched controls found that resting energy expenditure in PHP1a was roughly 350 fewer calories per day than in comparably obese children, even after adjusting for body composition.¹² That is a meaningful deficit; over weeks and months, burning 350 fewer calories per day at rest translates into substantial weight gain even when food intake is similar to peers.

Research in adults with PHP1a has confirmed this pattern, finding significantly decreased resting energy expenditure even when endocrine status was controlled with appropriate hormone replacement. The investigators concluded that the low metabolic rate, rather than excessive eating or untreated hormone problems, is the principal driver of obesity in this condition.¹³ Maternal GNAS mutations have separately been identified as a contributor to obesity in Albright hereditary osteodystrophy, with the parent-of-origin effect playing a key role: the same mutation on the paternal allele does not produce the same metabolic profile.¹⁴

Beyond the metabolic rate issue, adults with PHP1a have been found to have reduced insulin sensitivity compared with matched controls, which may contribute to glucose intolerance and raise the long-term risk of type 2 diabetes.¹⁵ This makes metabolic monitoring an important part of long-term care.

Cognitive and Behavioral Effects

Intellectual and developmental differences are common in PHP1a but are less well known among families who first receive the diagnosis. In a study of 16 children with PHP1a, the average composite IQ was about 86, roughly 17 points below matched controls. A quarter of the children tested below 70, which falls in the range of intellectual disability. Over half had been placed in self-contained special education classrooms, and many received occupational, physical, or speech therapy.¹⁶

A broader literature review found that cognitive impairment was present in about 79% of PHP1a cases with confirmed GNAS mutations, compared with only about 10% of PPHP patients carrying the same mutation on the paternal allele.¹⁷ The stark difference between PHP1a and PPHP suggests that Gsα imprinting extends to the brain, meaning the maternal allele may be the dominant contributor to Gsα production in certain brain regions. Hypothyroidism does not appear to explain the cognitive differences, as it was typically mild and treated promptly in the studied patients.

For families, this means that early developmental assessments and educational support should be part of the care plan for children with PHP1a. The range of ability is wide, with some children performing in the average range and others needing significant support, so individual evaluation matters more than assumptions based on the diagnosis alone.

How PHP Is Diagnosed

PHP is often first suspected when routine blood work shows low calcium and high phosphorus alongside an elevated PTH level. This combination sets PHP apart from ordinary hypoparathyroidism, where PTH is low or undetectable. The clinical and laboratory diagnosis should be confirmed by molecular genetic analysis.¹⁸ Genetic testing can identify the specific GNAS mutation or methylation abnormality, clarify which subtype is present, and inform genetic counseling for the family.

A urine-based test called the Ellsworth-Howard test, in which synthetic PTH is injected and the urinary response of phosphorus and cyclic AMP is measured, was historically used to confirm PTH resistance.¹⁹ In practice, the availability of molecular testing has made this less necessary, though it may still be used in settings where genetic analysis is not readily available. In PHP1a, the combination of the characteristic blood findings, AHO features, and a confirmed maternal GNAS mutation generally locks down the diagnosis.

Diagnosis can be trickier in PHP1b because these patients lack the obvious physical clues of AHO. They may present with hypocalcemia-related symptoms like tingling, cramping, or seizures without any prior suspicion of a genetic condition. Methylation analysis of the GNAS locus is the key diagnostic tool here. In sporadic PHP1b, which is the most common variant, the molecular mechanism remains only partly understood, though abnormal methylation at multiple GNAS regions is consistently found.³

Treating Low Calcium

The most urgent aspect of PHP treatment is correcting and maintaining calcium levels. Severe hypocalcemia can cause tetany (prolonged, painful muscle spasms), seizures, and cardiac rhythm disturbances. In acute episodes, intravenous calcium gluconate is given to bring levels up quickly.²⁰ One case report describes a PHP1a patient who presented with tetany, was stabilized with intravenous calcium in the emergency setting, and was then transitioned to oral calcium and calcitriol for ongoing maintenance.²¹

Long-term management relies on oral calcium supplements combined with active vitamin D, most commonly calcitriol. The majority of patients achieve good calcium control with calcitriol doses in the range of 0.5 to 2 micrograms per day, though doses vary.²² Calcitriol is preferred over plain vitamin D because the body’s ability to activate vitamin D in the kidneys depends partly on PTH signaling, which is impaired in PHP. High-dose cholecalciferol (the inactive form of vitamin D) can be used as an alternative, but the risk of toxicity after years of use is higher because of its longer duration of action in the body.

The goals of treatment are to keep ionized calcium within the normal range, to avoid pushing calcium too high (which can damage the kidneys through excessive urinary calcium), and in PHP specifically, to bring PTH levels down toward normal.²³ Because the body keeps making PTH in response to perceived calcium deficiency, successful calcium replacement brings PTH down as a secondary effect. Regular monitoring of blood calcium, phosphorus, PTH, and urinary calcium is essential throughout life.

Managing the Other Hormonal Deficiencies

Since PHP1a involves resistance to multiple hormones, treatment goes beyond calcium. Most patients need levothyroxine for hypothyroidism. A study examining dosing patterns in PHP patients found that those who achieved their PTH goals were often on higher calcitriol doses, and levothyroxine was frequently co-prescribed, reflecting the multihormone nature of the condition.²²

For children with confirmed growth hormone deficiency, recombinant growth hormone therapy may improve height and potentially benefit metabolic parameters like body composition, lipid levels, and bone density.¹¹ Gonadotropin resistance, when present, can delay puberty, and sex hormone replacement may be needed in affected adolescents. The overall treatment picture for PHP1a is essentially a collection of hormone replacements tailored to whatever signaling deficits the individual patient has, combined with close monitoring for complications like kidney calcification and metabolic syndrome.

Pregnancy and PHP

Pregnancy in women with PHP poses specific challenges because calcium requirements rise significantly during fetal development, and the already impaired calcium regulation has to work harder. In a retrospective Italian study that included three women with PHP, roughly 70% of patients with hypoparathyroidism or PHP maintained calcium levels in the low-to-mid normal range during pregnancy, but complications including preterm birth and miscarriage were observed in a meaningful minority.²⁴ A separate case report documented a successful pregnancy in a woman with PHP1a who was managed by a multidisciplinary team, with careful adjustment of calcitriol and calcium doses throughout gestation.²⁵

The practical takeaway is that pregnancy is possible with PHP but requires close collaboration between the patient’s endocrinologist and obstetrician. Calcium and calcitriol doses often need to be adjusted trimester by trimester, and frequent blood work is necessary to catch any drift in calcium levels before symptoms develop. Genetic counseling before conception is also important, since the condition is heritable and the parent of origin determines what the child will experience.

Cerebral and Renal Calcifications

Beyond the subcutaneous ossifications characteristic of AHO, people with PHP are at risk for calcium deposits in other locations, including the brain and kidneys. A study comparing PHP1a and PHP1b patients found that both subtypes could develop these calcifications. PHP1a patients tended to be diagnosed earlier and had higher rates of AHO features and hypertension, though biochemical values were similar between the two groups.²⁶

Brain calcifications in PHP most commonly appear in the basal ganglia, a finding that shows up on CT scans and is shared with other chronic hypocalcemic conditions. These calcifications are usually incidental findings and do not necessarily cause symptoms, but their presence reinforces the importance of maintaining calcium within the target range over the long term. Kidney calcifications are a more directly actionable concern because they can impair kidney function. Monitoring urinary calcium excretion helps guide calcitriol dosing to avoid overshooting the therapeutic target, and periodic kidney imaging may be warranted depending on the patient’s risk profile.

Living With a Lifelong Condition

PHP requires treatment for life, and the burden of that treatment is not trivial. Multiple daily medications, regular blood draws, periodic imaging, and specialist appointments are the norm. For children, the added layer of developmental support, growth hormone injections in many cases, and the social difficulties associated with short stature and obesity can weigh on families. Because the condition is rare, many primary care physicians and even general endocrinologists may not have extensive experience with it, so connecting with a center that specializes in rare endocrine disorders can make a real difference in care quality.

Genetic counseling deserves emphasis not just for family planning but also for understanding the inheritance pattern. A mother with PHP1a has a 50% chance of passing the GNAS mutation to each child, and because the mutation is on her maternal allele, her children who inherit it will also have PHP1a. A father with the same mutation would pass PPHP to his children, since his allele is the paternal one. This parent-of-origin asymmetry is one of the most counterintuitive aspects of the condition and can lead to confusion within families who see very different clinical pictures in relatives who carry the same genetic change.

1
PubMed Central. Pseudohypoparathyroidism
2
PubMed. Imprinting on chromosome 20: tissue-specific imprinting and imprinting mutations in the GNAS locus
3
The Journal of Clinical Endocrinology & Metabolism. Molecular Definition of Pseudohypoparathyroidism Variants
4
PubMed Central. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders
5
PubMed Central. An update on the clinical and molecular characteristics of pseudohypoparathyroidism
6
PubMed Central. A Novel Familial PHP1B Variant With Incomplete Loss of Methylation at GNAS-A/B and Enhanced Methylation at GNAS-AS2
7
PubMed Central. Albright hereditary osteodystrophy: a case report
8
The Journal of Clinical Endocrinology & Metabolism. Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI
9
PubMed. Late-onset subcutaneous scalp calcifications in a patient with pseudo-pseudohypoparathyroidism
10
PubMed. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance
11
PubMed Central. Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a
12
PubMed Central. Energy Expenditure in Obese Children with Pseudohypoparathyroidism Type 1a
13
PubMed Central. Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A
14
PubMed Central. The role of GNAS and other imprinted genes in the development of obesity
15
The Journal of Clinical Endocrinology & Metabolism. Reduced Insulin Sensitivity in Adults With Pseudohypoparathyroidism Type 1a
16
PubMed Central. Cognitive and Behavioral Phenotype of Children with Pseudohypoparathyroidism Type 1A
17
PubMed. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha
18
PubMed Central. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement
19
PubMed. Standard procedure and the diagnostic criteria for the Ellsworth-Howard test using human PTH-(1-34)
20
PubMed. Hypocalcemic emergencies
21
Journal of Medical Sciences and Health. Pseudohypoparathyroidism Type 1a Manifested with Tetany: A Rare Case Scenario
22
PubMed Central. Calcitriol and Levothyroxine Dosing for Patients With Pseudohypoparathyroidism
23
Chinese Medical Journal. Treatment of hypocalcemia caused by hypoparathyroidism or pseudohypoparathyroidism with domestic-made calcitriol: a prospective and self-controlled clinical trial
24
PubMed Central. Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study
25
PubMed Central. Management of Pseudohypoparathyroidism Type 1a during Pregnancy and Labor: A Case Report
26
The Journal of Clinical Endocrinology & Metabolism. Pseudohypoparathyroidism: Focus on Cerebral and Renal Calcifications